Table 1.
Characteristics | No. of patients | Percent of patients (%) | Mean±SD | P value |
---|---|---|---|---|
Age (years) | ||||
≥50 | 84 | 78.5 | 12.05±1.34 | .714 |
<50 | 23 | 21.5 | 12.17±1.37 | |
Gender | ||||
Male | 96 | 89.7 | 12.14±1.34 | .611 |
Female | 11 | 10.3 | 11.53±1.25 | |
Family history | ||||
Positive | 72 | 67.3 | 12.18±1.35 | .244 |
Negative | 35 | 32.7 | 11.86±1.30 | |
Diabetes mellitus | ||||
Yes | 14 | 13.1 | 12.14±1.27 | .844 |
No | 93 | 86.9 | 12.06±1.36 | |
Encapsulation | ||||
Yes | 69 | 64.5 | 11.98±1.32 | .360 |
No | 38 | 35.5 | 12.24±1.38 | |
Tumor number | ||||
Single | 74 | 69.2 | 12.03±1.39 | .626 |
Multiple | 33 | 30.8 | 12.16±1.23 | |
Diameter (cm) | ||||
≥5 | 45 | 42.1 | 12.40±1.43 | .035 |
<5 | 62 | 57.9 | 11.84±1.23 | |
Differentiation | ||||
Poor | 17 | 15.9 | 12.84±1.27 | .013 |
Moderate and Well | 90 | 84.1 | 11.93±1.31 | |
Microvascular invasion | ||||
Positive | 45 | 43.7 | 12.39±1.56 | .046 |
Negative | 58 | 56.3 | 11.86±1.12 | |
BCLC stage | ||||
A | 45 | 42.1 | 11.63±1.18 | .011 |
B | 42 | 39.2 | 12.45±1.33 | |
C+D | 20 | 18.7 | 12.28±1.47 | |
TNM stage | ||||
I | 44 | 41.1 | 11.72±1.13 | .016 |
II+III+IV | 63 | 58.9 | 12.32±1.42 | |
HbsAg | ||||
Negative | 15 | 14.3 | 11.88±1.24 | .547 |
Positive | 90 | 85.7 | 12.11±1.37 | |
Serum AFP | ||||
>20 | 63 | 61.2 | 12.29±1.29 | .031 |
≤20 | 40 | 38.8 | 11.70±1.35 | |
Serum AKP | ||||
>95 | 58 | 54.2 | 11.95±1.30 | .303 |
≤95 | 49 | 45.8 | 12.22±1.38 | |
Serum GGT | ||||
>50 | 58 | 54.2 | 12.26±1.37 | .125 |
≤50 | 49 | 45.8 | 11.86±1.29 |
TNM, tumor‐node‐metastasis; BCLC, Barcelona Clinic Liver Cancer staging system; AFP, alpha‐fetoprotein; AKP, alkaline phosphatase; GGT: gamma glutamyl transferase.